Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.
Page EC [et al]. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. European Urology. 2019 Dec;76(6):831-842